Skip navigation

ATTORNEYS AT LAW

Cases
Who We Are
- Scott+Scott LLP is a nationally recognized law firm headquartered in Connecticut with offices in New York City, Ohio and California. The firm represents individual as well as institutional investors who have suffered from corporate stock fraud. Scott+Scott has participated in recovering billions of dollars and achieved precedent-setting reforms in corporate governance on behalf of its clients. In addition to being involved in complex shareholder securities and corporate governance actions, Scott+Scott also has a significant national practice in antitrust, ERISA, consumer, civil rights and human rights litigation. Through its efforts, Scott+Scott promotes corporate social responsibility… read more
Our Practice
- Securities Fraud + Corporate Governance +
  
  Scott + Scott is a nationally recognized law firm that recovers money for individual and institutional… read more
- Antitrust +
  
  The firm is actively involved in litigating many complex antitrust cases throughout the United States… read more
- Consumer Rights +
  
  Scott + Scott regularly represents aggrieved consumers in a variety of class action cases… read more
- Employee Benefits (ERISA) +
  
  Scott + Scott actively litigates complex class actions across the United States on behalf of corporate employees… read more
Attorneys
- The attorneys in our firm are a diverse and accomplished group, with degrees from a variety of law schools, including Yale University, University of Wisconsin, University of Connecticut, University of Kentucky, New York University, University of Chicago, Temple University, George Washington University, University of Washington, University of San Diego, University of California, Ohio State University, Boston College and Boston University. Many graduated with distinction and were members and editors of their respective schools' law reviews, moot courts or honor fraternities. Several have served federal or state judicial clerkships. Others hold graduate degrees in law, tax or other disciplines… read more
Pressbox
- Scott+Scott LLP maintains a regular media presence, publishing informative articles on a regular basis, as well as appearing frequently in the news… read more
FAQ
- The following questions and answers provide general information about securities class actions, derivitive litigation, and ERISA class actions. They are not legal advice.
- Securities Class Actions +
- Securities Class Actions and the non-U.S. Investor +
- Shareholder Derivative Actions +
- ERISA 401(k)/Pension Retirement Benefit Class Actions +
Contact Us
- Connecticut
  
  Scott+Scott LLP
  156 South Main Street
  P.O. Box 192
  Colchester, CT 06415
  800.404.7770 toll-free
  860.537.5537 voice
  860.537.4432 fax
- California
  
  Scott+Scott LLP
  600 B Street
  Suite 1500
  San Diego, CA 92101
  800.332-2259 toll-free
  619.233.4565 voice
  619.233.0508 fax
- Ohio
  
  Scott+Scott LLP
  12434 Cedar Road
  Suite 12
  Cleveland Heights, OH 44106
  216.229.6088 voice
  216.229.6092 fax
- New York
  
  Scott+Scott LLP
  500 5th Avenue
  Floor 40
  New York, NY 10110
  800-404-7770 toll-free
  212.223.6444 voice
  212.223.6334 fax
- *Los Angeles Annex Office
  
  Scott+Scott LLP
  6424 Santa Monica Boulevard
  Los Angeles, CA 90038
  213.985.1274, 213.985.1278 (fax)
  
  scottlaw@scott-scott.com
  
  UK Tel: 0808 234 1396
Search
- Go

New Cases

CASES

Accuray Inc.

Class Period: Feb 7, 2007 to Aug 19, 2008

Lead Plaintiff Deadline: Sep 21, 2009 + Deadline passed

Summary of Case:

Summary of the Case:

A securities class action has been filed against Accuray Inc. (ARAY) ("Accuray" or the "Company") on behalf of all securities purchasers from February 7, 2007 through August 19, 2008, inclusive ("Class Period") in the United States District Court for the Northern District of California.

The complaint alleges that Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radio surgery system for the treatment of solid tumors. The CyberKnife system combines continuous image-guidance technology with a compact linear accelerator to deliver high doses of radiation to a tumor from different directions.

During the Class Period, defendants misrepresented and failed to disclose material information concerning the quality and realistic likelihood of fulfillment of contracts in Accuray's "backlog," a figure representing the direct revenue that Accuray expects to receive from the sale and servicing of the CyberKnife system. Specifically, defendants misrepresented and/or failed to disclose the following adverse facts: (i) at the time of Accuray's Initial Public Offering (the "IPO"), Accuray changed its definition of backlog to include both contingent and non-contingent contracts; (ii) beginning in the fiscal quarter ending March 31, 2007 (at the time of the IPO), Accuray would report backlog that consisted of both contingent and non-contingent backlog, thereby increasing the total reported backlog; (iii) defendants materially overstated the amount of the Company's backlog; (iv) Accuray reported as backlog orders for the CyberKnife system that did not have a substantially high probability of being booked as revenue; (v) a significant portion of commissions paid to CyberKnife sales personnel were earned prior to those potential sales being booked as revenue; (vi) Accuray sales personnel entered into contingent contracts for CyberKnife systems that did not have a substantially high probability of being booked as revenue; (vii) Accuray did not have adequate internal controls and procedures to ensure that potential orders reported as backlog had a substantially high probability of being booked as revenue; and (viii) based on the foregoing, defendants lacked a reasonable basis for their positive statements about the Company, its backlog, earnings, operations and prospects.

On August 19, 2008, Accuray announced its fiscal fourth quarter and full year 2008 financial results for the period ended June 28, 2008 in a press release titled "Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008; 28 New Contracts Valued at $115.5 Million Signed in Fourth Quarter". That same day, Accuray held a conference call with analysts and reiterated the financial results in the press release and revealed that Accuray removed another $39 million from backlog. Thus, Accuray removed approximately $127 million in backlog during the last three quarters of fiscal 2008.

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.